111 related articles for article (PubMed ID: 22704290)
1. Development of PK- and PBPK-based modeling tools for derivation of biomonitoring guidance values.
Bartels M; Rick D; Lowe E; Loizou G; Price P; Spendiff M; Arnold S; Cocker J; Ball N
Comput Methods Programs Biomed; 2012 Nov; 108(2):773-88. PubMed ID: 22704290
[TBL] [Abstract][Full Text] [Related]
2. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.
Aylward LL; Kirman CR; Blount BC; Hays SM
Regul Toxicol Pharmacol; 2010 Oct; 58(1):33-44. PubMed ID: 20685286
[TBL] [Abstract][Full Text] [Related]
3. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme.
Boogaard PJ; Hays SM; Aylward LL
Regul Toxicol Pharmacol; 2011 Feb; 59(1):125-32. PubMed ID: 20933039
[TBL] [Abstract][Full Text] [Related]
4. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene.
Liao KH; Tan YM; Clewell HJ
Risk Anal; 2007 Oct; 27(5):1223-36. PubMed ID: 18076492
[TBL] [Abstract][Full Text] [Related]
5. A new method for generating distributions of biomonitoring equivalents to support exposure assessment and prioritization.
Phillips MB; Sobus JR; George BJ; Isaacs K; Conolly R; Tan YM
Regul Toxicol Pharmacol; 2014 Aug; 69(3):434-42. PubMed ID: 24845241
[TBL] [Abstract][Full Text] [Related]
6. Biomonitoring Equivalents for benzene.
Hays SM; Pyatt DW; Kirman CR; Aylward LL
Regul Toxicol Pharmacol; 2012 Feb; 62(1):62-73. PubMed ID: 22178585
[TBL] [Abstract][Full Text] [Related]
7. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
8. Biomonitoring equivalents for DDT/DDE.
Kirman CR; Aylward LL; Hays SM; Krishnan K; Nong A
Regul Toxicol Pharmacol; 2011 Jul; 60(2):172-80. PubMed ID: 21466830
[TBL] [Abstract][Full Text] [Related]
9. Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH.
Boogaard PJ; Aylward LL; Hays SM
Int J Hyg Environ Health; 2012 Feb; 215(2):238-41. PubMed ID: 22177527
[TBL] [Abstract][Full Text] [Related]
10. Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context.
Hays SM; Aylward LL
J Appl Toxicol; 2009 May; 29(4):275-88. PubMed ID: 19115313
[TBL] [Abstract][Full Text] [Related]
11. Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents.
Hays SM; Aylward LL
Int J Hyg Environ Health; 2012 Feb; 215(2):145-8. PubMed ID: 22192580
[TBL] [Abstract][Full Text] [Related]
12. Interpreting variability in population biomonitoring data: role of elimination kinetics.
Aylward LL; Kirman CR; Adgate JL; McKenzie LM; Hays SM
J Expo Sci Environ Epidemiol; 2012 Jul; 22(4):398-408. PubMed ID: 22588214
[TBL] [Abstract][Full Text] [Related]
13. 2,4-D exposure and risk assessment: comparison of external dose and biomonitoring based approaches.
Hays SM; Aylward LL; Driver J; Ross J; Kirman C
Regul Toxicol Pharmacol; 2012 Dec; 64(3):481-9. PubMed ID: 23017741
[TBL] [Abstract][Full Text] [Related]
14. Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7).
Aylward LL; Hays SM; Gagné M; Krishnan K
Regul Toxicol Pharmacol; 2009 Dec; 55(3):249-58. PubMed ID: 19751789
[TBL] [Abstract][Full Text] [Related]
15. Reverse dosimetry modeling of toluene exposure concentrations based on biomonitoring levels from the Canadian health measures survey.
Tohon H; Nong A; Moreau M; Valcke M; Haddad S
J Toxicol Environ Health A; 2018; 81(20):1066-1082. PubMed ID: 30365389
[TBL] [Abstract][Full Text] [Related]
16. Biomonitoring equivalents for deltamethrin.
Aylward LL; Krishnan K; Kirman CR; Nong A; Hays SM
Regul Toxicol Pharmacol; 2011 Jul; 60(2):189-99. PubMed ID: 21466827
[TBL] [Abstract][Full Text] [Related]
17. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results.
Jongeneelen FJ; Berge WF
Ann Occup Hyg; 2011 Oct; 55(8):841-64. PubMed ID: 21998005
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: application of chemical-specific screening criteria.
Kirman CR; Aylward LL; Blount BC; Pyatt DW; Hays SM
J Expo Sci Environ Epidemiol; 2012; 22(1):24-34. PubMed ID: 21989501
[TBL] [Abstract][Full Text] [Related]
19. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
20. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform.
Tan YM; Liao KH; Conolly RB; Blount BC; Mason AM; Clewell HJ
J Toxicol Environ Health A; 2006 Sep; 69(18):1727-56. PubMed ID: 16864423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
